KEGG   DRUG: Rilvegostomig
Entry
D12764                      Drug                                   
Name
Rilvegostomig (USAN/INN)
Formula
C6468H9961N1735O2017S46
Exact mass
145682.7366
Mol weight
145772.79
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYGMHWVRQA PGKGLEWVAY ISSGSYTIYS
ADSVKGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCARRA PNSFYEYYFD YWGQGTTVTV
SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPEFE
GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPASIEKT ISKAKGQPRE PQVCTLPPSR
EEMTKNQVSL SCAVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LVSKLTVDKS
RWQQGNVFSC SVMHEALHNH YTQKSLSLSP GK
(heavy chain)
QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYAMHWVRQA PGKGLEWVAV ISYAGEVKYY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARDP LPLHYYGMDV WGQGTTVTVS
SASTKGPSVC PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP SNTKVDKRVE PKSVDKTHTC PPCPAPEFEG
GPSVFLFPPK PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPASIEKTI SKAKGQPREP QVYTLPPCRE
EMTKNQVSLW CLVKGFYPSD IAVEWESNGQ PENNYKTTPP VLDSDGSFFL YSKLTVDKSR
WQQGNVFSCS VMHEALHNHY TQKSLSLSPG K
(Light chain)
QIVLTQSPAT LSLSPGERAT LSCSASSKHT NLYWSRHMYW YQQKPGQAPR LLIYLTSNRA
TGIPARFSGS GSGTDFTLTI SSLEPEDFAV YYCQQWSSNP FTFGQGTKLE IKRTVAAPSV
FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL
SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
(light chain)
QSVLTQPPSA SGTPGQRVTI SCSGSSSNIG RRPVNWYQQL PGTAPKLLIY SQNQRPSGVP
DRFSGSQSGT SASLAISGLQ SEDEADYFCA VWDDIGRVLQ LGGGTQLTVL GQPKAAPSVT
LFPPCSEELQ ANKATLVCLI SDFYPGAVTV AWKADSSPVK AGVETTTPSK QSNNKYAASS
YLSLTPEQWK SHRSYSCQVT HEGSTVEKTV APTEVS
(disulfide bridge: H22-H96, H149-H205, H225-L219, H231-h230, H234-h233, H266-H326, H354-h358, H372-H430, h22-h96, h130-l125, h148-h204, h265-h325, h371-h429, L23-L93, L139-L199, l22-l89, l138-l197)
  Type
Peptide
Class
Antineoplastic
 DG02938  Immune checkpoint inhibitor
Efficacy
Antineoplastic, Immune checkpoint inhibitor
  Type
Monoclonal antibody, bispecific antibody
Target
PDCD1 (PD1, CD279) [HSA:5133] [KO:K06744]
TIGIT [HSA:201633] [KO:K16350]
  Pathway
hsa04514  Cell adhesion molecules
hsa04660  T cell receptor signaling pathway
hsa05235  PD-L1 expression and PD-1 checkpoint pathway in cancer
Brite
Drug groups [BR:br08330]
 Antineoplastic
  DG02938  Immune checkpoint inhibitor
   D12764  Rilvegostomig
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   Immune checkpoints
    PDCD1 (PD1, CD279)
     D12764  Rilvegostomig (USAN/INN)
    TIGIT
     D12764  Rilvegostomig (USAN/INN)
Other DBs
CAS: 2640305-01-5
PubChem: 497621177
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system